Counterfeit Drugs
(1999; 61 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentExecutive Summary
Ouvrir ce répertoire et afficher son contenu1. Introduction
Afficher le document2. Overview of the problem
Afficher le document3. Impact on public health
Afficher le document4. Factors facilitating counterfeiting
Ouvrir ce répertoire et afficher son contenu5. Developing national strategies
Ouvrir ce répertoire et afficher son contenu6. Specific measures
Fermer ce répertoire7. Assessment of the problem at the national level
Afficher le document7.1 Approaches
Afficher le document7.2 Sampling procedures
Afficher le document7.3 Limitations
Ouvrir ce répertoire et afficher son contenu8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Ouvrir ce répertoire et afficher son contenu9. Test methods
Ouvrir ce répertoire et afficher son contenu10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
Afficher le document11. Conclusion
Afficher le documentReferences
Afficher le documentSelected further reading
Afficher le documentAcknowledgements
Afficher le documentGlossary
 

7.3 Limitations

It is important to be aware of the limitations of country studies. For example, the nature of counterfeiting depends on the specific demand for and availability of certain categories of drugs at any given time in a country. The results of the study may therefore be influenced by the time at which sampling is undertaken.

Random sampling of selected drugs may not necessarily be the best way to find counterfeit drugs, especially if the numbers of counterfeits are few. Moreover, it may be difficult to obtain the required number of samples, or the desired number of sample units from the same batch at one outlet.

The covert purchase of samples from unauthorized outlets may pose serious problems. For example, the vendors may become suspicious of the intent if many samples of one particular batch or batches were sought and purchased. Suspicions might also be aroused if attempts are made to procure samples from more than one outlet in the same area. It is also unlikely that the national DRA could easily obtain the necessary information from the actual manufacturer of the suspected drug.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012